Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.
Inclusion Criteria:
Exclusion Criteria:
Rancagua, Región del Libertador General Bernardo O’Higgins 2841959, Chile
Praha 11 - Chodov, 148 00, Czechia
Randers NOE, 8930, Denmark
Santo Domingo, Santo Domingo Province 00000, Dominican Republic
Povazska Dystrica, 017 01, Slovakia
Rajathevee, Bangkok 10400, Thailand
Amphoe Muang, Chiang Mai 50200, Thailand